The Globe and Mail reports in its Wednesday, Jan. 28, edition that Canaccord Genuity analyst Kenric Tyghe rates Organigram Global "buy" in new coverage. The Globe's David Leeder writes in the Eye On Equities column that Mr. Tyghe set a share target of $3. Analysts on average target the shares at $3.62. Mr. Tyghe believes the Canadian cannabis market is a global benchmark for legal commercialization, with potential for growth through regulatory reform, consolidation and international expansion, despite some challenges. Mr. Tyghe says in a note: "Organigram Global is accelerating its transition from a mid-tier LP to a vertically integrated global cannabis company, with market-leading positions in key categories in Canada, including the number one share in pre-rolls, concentrates, milled flower and vapes (and top three in flower and gummies). The company, supported by the acquisition of Motif Labs on Dec. 6, 2024, further extended its leading recreational market share in Canada to 11.9 per cent in F2025. Organigram's growth, balance sheet flexibility and competitive positioning since 2021 have materially benefitted from strategic investments by British American Tobacco PLC totaling $345-million."